查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2103732

皮質類固醇療法市場：全球市場預測，2026-2032年

Corticosteroids Therapy Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，皮質類固醇治療市場將成長至 91.3 億美元，複合年成長率為 5.31%。

主要市場統計數據
基準年 2025 63.5億美元
預計年份：2026年 66.8億美元
預測年份 2032 91.3億美元
複合年成長率 (%) 5.31%

糖皮質激素療法仍然是現代醫學的基石，糖皮質激素和鹽皮質激素被廣泛應用於多種疾病領域，包括發炎性疾病、自體免疫疾病、過敏性疾病、皮膚病、呼吸系統疾病、眼科疾病、風濕性疾病、內分泌疾病以及移植相關疾病。其臨床應用形式多樣，涵蓋口服、注射、吸入、鼻腔、局部用藥、眼藥水和關節內注射等劑型，使醫生能夠根據患者的病情和風險狀況調整藥物的效力、起效時間、持續時間和全身暴露量。在慢性呼吸系統疾病、自體免疫疾病、嚴重過敏、發炎性皮膚病和急性治療等全球疾病負擔較高的領域，糖皮質激素療法已被納入實證治療方案，這為其應用提供了支持。然而，皮質類固醇存在一些已知的安全隱患，包括高血糖、高血壓、骨質疏鬆、感染風險、腎上腺抑制、眼部併發症和皮膚萎縮。因此，劑量最佳化、給藥持續時間管理、患者監測和類固醇節約策略在臨床決策中至關重要。因此，目前皮質類固醇治療的特點是兩個重點：在保持快速可靠的抗發炎和免疫抑製作用的同時，透過改進給藥系統、局部用藥、合理用藥和綜合護理方案來減少累積副作用。

皮質類固醇療法現況的變革性變化

目前，糖皮質激素治療正從廣泛且長期的全身性用藥轉向更精準、針對特定適應症且注重安全性的用藥。在呼吸內科，吸入和鼻內糖皮質激素繼續用於支持基於指南的氣喘、過敏性鼻炎和某些慢性阻塞性肺病（COPD）表現型的治療，同時越來越關注用藥依從性、吸入技術和聯合治療。在皮膚科和眼科，局部和外用糖皮質激素的使用更加謹慎，注重療效選擇、治療週期管理和副作用預防。在風濕病科、胃腸病科、腎臟科和免疫科，臨床醫生越來越關注如何平衡糖皮質激素誘導治療的益處與早期過渡到維持治療以減少長期糖皮質激素負擔。此外，皮質類固醇在嚴重發炎和呼吸系統併發症中的廣泛臨床經驗促使醫院治療方案更加標準化，並再次強調了合理選擇患者和給藥時機的重要性。由於皮質類固醇會改變免疫反應，監管和臨床實踐趨勢正在加強藥物安全監測，完善附加檔，明確兒童用藥注意事項，評估懷孕相關風險，並推廣合理使用抗生素。這些變化促使製藥公司、醫療系統和處方醫生更加關注差異化製劑、患者教育、數位化用藥依從性支持以及真實世界數據（REW）的生成，而不是僅依賴傳統的處方模式。

人工智慧對皮質類固醇療法的累積影響

人工智慧 (AI) 透過改善藥物研發、臨床決策支援、藥物安全監測和患者管理，正在為皮質類固醇治療創造累積價值。在藥物研發方面，AI 驅動的分子建模和計算生物學能夠評估下一代皮質類固醇候選藥物和藥物遞送技術的受體結合、組織選擇性、製劑行為以及潛在的脫靶效應。在臨床實踐中，AI 驅動的決策工具分析患者病歷、共病、實驗室指標變化趨勢、用藥依從性、病情加重模式以及影像學和肺功能檢查數據，從而支持更安全地啟動、減量和監測皮質類固醇治療，尤其是在複雜的發炎性疾病中。自然語言處理可用於從電子健康記錄中識別皮質類固醇相關的不利事件，而預測分析可用於識別類固醇誘發高血糖、骨質疏鬆、感染疾病、腎上腺抑製或用藥依從性差的高風險患者。此外，人工智慧將整合保險理賠數據、登記數據、處方數據和患者報告結局，從而增強真實世界證據，以評估皮質類固醇療法在非對照檢驗環境中的療效。然而，臨床有效性、透明度、偏倚管理、網路安全措施以及與醫療指南的一致性對於人工智慧的實施至關重要。人工智慧在以下領域預計將發揮最大作用：輔助臨床醫生判斷、支持個體化劑量設定和安全性監測，以及在不影響疾病管理的前提下幫助減少不必要的皮質類固醇暴露。

關於皮質類固醇療法的關鍵區域見解

在亞太地區，皮質類固醇療法廣泛用於治療呼吸系統疾病、皮膚病、眼科疾病、過敏性疾病和自體免疫疾病。這得益於大規模的患者群體、不斷擴大的醫療服務覆蓋範圍以及對價格低廉的非專利藥的依賴。在空氣污染嚴重、吸菸相關呼吸道疾病負擔沉重以及過敏症盛行率不斷上升的國家，吸入、鼻用和局部用皮質類固醇的臨床應用更為突出。同時，專科醫療的擴張也促進了皮質類固醇在風濕病、胃腸病和腎臟病等領域的系統性應用。在歐洲，皮質類固醇的處方受到嚴格監管，安全標籤全面詳盡，基層醫療和專科醫療之間密切合作，並持續致力於局部給藥、藥物安全監測以及減少長期全身用藥。在北美，基於指引的皮質類固醇治療方案已成熟實施，不利事件報告系統健全，患者可獲得先進的專科醫療服務，並且越來越重視減少類固醇用量、慢性病監測和數位化用藥依從性工具。在拉丁美洲，急性和慢性發炎性疾病對皮質類固醇的依賴程度保持穩定，但患者取得藥物的途徑受到以下因素的影響：需要加強對公共保險報銷、私人醫療保健服務、當地藥品目錄、自我用藥以及適當療程等方面的患者教育。在非洲，雖然皮質類固醇在初級保健、急診、呼吸系統疾病、皮膚病和產科護理中必不可少，但其可及性、診斷能力、經濟負擔和監測系統存在顯著差異，因此合理用藥、確保藥物供應的連續性以及提高對不利事件的認知至關重要。在中東，尤其是在那些投資於專科診所、電子健康記錄和先進診斷技術的醫療系統中，呼吸系統疾病負擔的加重、過敏症患病率的上升、糖尿病相關監測需求的增加以及三級醫療基礎設施的不斷完善，都對皮質類固醇治療產生了影響。

關於皮質類固醇治療的關鍵群體特異性見解

在北約成員國（其中許多國家的醫療保健系統與高所得國家的醫療保健系統重疊），重點在於藥品安全、緊急準備、醫院處方集和標準化診療路徑，以確保在日常診療、創傷護理以及急性發炎和呼吸系統急症中可靠地獲得皮質類固醇。在七國集團（G7）國家，普遍採用實證先進療法，提供多種劑型，並建立健全的不利事件通報系統，同時，在臨床適宜的情況下，尤其是在氣喘、風濕病、皮膚病、發炎性腸道疾病和移植醫學領域，越來越傾向採用非類固醇類藥物替代療法。金磚國家擁有大規模的患者群體，積極使用學名藥，國內製藥能力不斷提升，且專科醫療保健需求日益成長，因此，可負擔性、品質保證、合理使用抗生素和供應穩定性已成為皮質類固醇治療的核心主題。歐盟在法律規範、藥物安全監測基礎設施和臨床指南的採納方面具有優勢，這有助於在成員國之間實現一致的安全監測、替代標準和合理使用皮質類固醇。另一方面，報銷制度和區域處方習慣的差異仍然影響著藥物的可近性。在東協地區，皮質類固醇治療受到人口眾多、呼吸系統和過敏性疾病、熱帶皮膚病高發以及公共醫療保險覆蓋範圍擴大等因素的影響，因此需要持續對臨床醫生進行安全劑量、感染疾病相關風險評估和患者依從性方面的教育。在海灣合作理事會國家，重點在於專科醫療、醫院現代化、糖尿病患者用藥指導以及慢性呼吸系統和自體免疫疾病的管理，並正在推廣採用先進製劑和系統監測，尤其是在已實施數位健康計畫的地區。

主要國家皮質類固醇治療趨勢

在中國，糖皮質激素療法廣泛用於呼吸系統疾病、過敏、皮膚病、眼科疾病和自體免疫疾病的治療，並持續投資改善醫療服務可近性、發展國內生產以及規範臨床實踐。在美國，糖皮質激素療法廣泛用於基層醫療、急診醫學、呼吸內科、皮膚科、風濕病科、消化內科、移植醫學和眼科，臨床重點在於遵循指南、減少激素用量、電子處方管理以及監測激素引起的代謝和骨骼併發症。日本的特點是高度專業化的醫療服務、對老齡化相關發炎和自體免疫疾病的管理以及嚴格的安全監測，而印度則廣泛用於氣喘、皮膚病、急診醫學、自體免疫疾病以及感染疾病和發炎性疾病的鑑別診斷，合理用藥、價格可承受性、診斷準確性和患者教育尤為重要。德國的特點是臨床高度標準化、醫療服務高度專業化以及藥物安全監測嚴密，尤其是在慢性發炎性疾病的治療方面。在英國，系統性處方以基層醫療和專科指南為基礎，重點關注氣喘管理、口服類固醇的合理使用以及副作用監測。在澳大利亞，基於指南的皮質類固醇使用已應用於氣喘、過敏、皮膚病、風濕病和眼科，並與基層醫療密切合作。在法國，皮質類固醇的報銷體系和臨床監管體系健全，重點在於獲益風險評估和病患諮詢。在韓國，先進的醫療基礎設施、高普及率的數位醫療以及皮質類固醇製劑的廣泛可近性，共同支持了系統性監測和用藥依從性管理。在義大利和西班牙，皮質類固醇廣泛應用於呼吸系統、風濕病、皮膚病、胃腸道和眼科疾病的治療，並日益關注老年患者、多種合併症以及盡量減少慢性全身暴露。在加拿大，重點在於循證處方、協調公共和私人保險報銷以及慢性病管理，吸入、鼻內、局部和全身性皮質類固醇均已納入呼吸系統和皮膚科的臨床實踐。在俄羅斯，皮質類固醇在所有醫療機構（包括住院和門診）均被廣泛使用，基本製劑的供應和專科醫生的診療途徑影響著治療模式。在巴西，大規模的公共醫療體係以及呼吸系統、皮膚病、過敏和自體免疫疾病方面的巨大醫療需求，使得獲得經濟有效的皮質類固醇製劑和轉診途徑至關重要。同時，在墨西哥，皮質類固醇被廣泛用於治療急性發炎、過敏、呼吸系統疾病和皮膚病，但其監督使用和減少不當自我用藥方面仍有改進空間。

為行業領導者提供的實用建議

產業領導者應優先考慮差異化的皮質類固醇療法，以改善局部給藥、降低全身暴露，並支持更安全地長期管理慢性發炎性疾病。產品開發應著重最佳化吸入劑、鼻噴劑、外用製劑、眼藥水、注射劑、關節內注射劑和緩釋製劑，以解決用藥依從性、給藥便利性、起效時間和耐受性等問題。實證策略應包括真實世界研究，評估不同族群的不利事件、用藥依從性、減重療效、合併症風險、累積暴露量和病人報告結果。醫學教育應強調合理選擇適應症、最短有效給藥療程、減重方案、正確使用吸入器、局部用藥療效指導以及代謝、骨骼、眼睛、皮膚、內分泌、精神和感染疾病相關風險的監測。數位化工具可透過支持用藥依從性提醒、症狀追蹤、病情加重警報、電子用藥史以及用於了解累積固醇暴露量的臨床醫師儀表板來增加價值。准入團隊應優先考慮基本藥物的可負擔性、可及性、品質保證和報銷的一致性，尤其是在高度依賴學名藥的醫療體系中。供應鏈管理人員應加強用於急診、基層醫療、母嬰、呼吸系統、皮膚科、眼科和住院等場所的基本皮質類固醇製劑的供應鏈韌性。最後，各機構應將創新與減少類固醇用量的護理模式結合，將皮質類固醇定位為綜合治療路徑的一部分，而非孤立的干預措施。

調查方法

本執行摘要採用結構化的二級研究途徑編寫，重點檢驗的臨床、監管、流行病學和醫療服務資訊來源。該調查方法包括對同行評審的醫學文獻、臨床實踐指南、藥物安全監測框架、公共衛生出版物、藥物安全資訊、基本藥物參考文獻、疾病負擔研究以及與皮質類固醇治療相關的監管文件的審查。分析考慮了給藥途徑、臨床適應症、安全性概況、處方趨勢、醫療基礎設施、可近性、報銷狀況和區域政策環境。透過定性整合區域、群體和國家層面的見解，識別皮質類固醇使用、安全管理、劑型選擇、融入治療路徑以及醫療系統發展方面的實證模式。為了專注於臨床和策略見解，本摘要有意排除了市場估算和預測、市場規模計算、市場佔有率評估和預測。所有研究結果均以實際決策為導向，供參與皮質類固醇開發、分銷、處方支持、藥物安全監測和患者照護最佳化的相關人員參考。

結論

儘管皮質類固醇療法在急性和慢性發炎性疾病中仍然至關重要，但其未來取決於更安全、更個人化和實證的應用。該領域正朝著局部給藥、降低全身負擔、更嚴格的監測、減少類固醇用量的治療路徑以及加強病患教育的方向發展。人工智慧、真實世界證據和數位健康工具正在增強識別風險、提高用藥依從性和指南個人化治療決策的能力。醫療保健、監管、專科醫生資源、經濟負擔和藥物安全監測方面的區域差異將繼續影響皮質類固醇的使用，尤其是在新興經濟體和資源匱乏的環境中。產業領導者面臨的最大機會在於提高製劑性能、最佳化處方支援、加強安全監測、確保供應連續性以及將皮質類固醇整合到現代慢性病管理模式中。透過平衡已證實的治療價值和嚴格的風險緩解措施，皮質類固醇療法可以繼續成為全球醫療保健中至關重要且值得信賴的組成部分。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：皮質類固醇治療市場：依藥物類型分類

  • Budesonide
  • 地塞米松
  • Hydrocortisone
  • Methylprednisolone
  • 強的松

第8章：皮質類固醇治療市場：依給藥途徑分類

  • 吸入
    • 乾粉吸入器
    • 定量噴霧吸入器
    • 噴霧器
  • 注射藥物
    • 肌肉內部
    • 靜脈
    • 皮下
  • 口服
    • 懸浮液
    • 藥片
  • 外用
    • 奶油
    • 洗劑
    • 軟膏

第9章：皮質類固醇治療市場：以劑型分類

  • 奶油
  • 注射藥物
  • 懸浮液
  • 藥片

第10章：皮質類固醇治療市場：依適應症分類

  • 過敏性鼻炎
  • 氣喘
  • 皮膚病
  • 發炎性腸道疾病
  • 類風濕性關節炎

第11章：皮質類固醇治療市場：依患者年齡層分類

  • 成人
  • 老年人
  • 兒童

第12章：皮質類固醇治療市場：依地區分類

  • 亞太地區
  • 歐洲
  • 北美洲
  • 拉丁美洲
  • 非洲
  • 中東

第13章：皮質類固醇治療市場：依組別分類

  • NATO
  • G7
  • BRICS
  • EU
  • ASEAN
  • GCC

第14章：皮質類固醇治療市場：依國家分類

  • 中國
  • 美國
  • 日本
  • 印度
  • 德國
  • 英國
  • 澳洲
  • 法國
  • 韓國
  • 義大利
  • 加拿大
  • 俄羅斯
  • 巴西
  • 墨西哥
  • 西班牙

第15章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Abbott Laboratories
  • Allergan PLC
  • Amgen Inc.
  • AstraZeneca PLC
  • Biogen Inc.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Cipla Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • Galderma Group
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Lupin Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • SANTHERA PHARMACEUTICALS
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-C002B1C9976A

The Corticosteroids Therapy Market is projected to grow by USD 9.13 billion at a CAGR of 5.31% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.35 billion
Estimated Year [2026] USD 6.68 billion
Forecast Year [2032] USD 9.13 billion
CAGR (%) 5.31%

Corticosteroids therapy remains a cornerstone of modern medicine because glucocorticoids and mineralocorticoids are used across inflammatory, autoimmune, allergic, dermatologic, respiratory, ophthalmic, rheumatologic, endocrine, and transplant-related conditions. Clinical use spans oral, injectable, inhaled, intranasal, topical, ophthalmic, and intra-articular formulations, allowing physicians to tailor potency, onset, duration, and systemic exposure to the patient's condition and risk profile. Utilization is supported by the high global burden of chronic respiratory diseases, autoimmune disorders, severe allergies, inflammatory skin diseases, and acute care indications in which corticosteroids are embedded in evidence-based treatment pathways. At the same time, corticosteroids are associated with well-documented safety considerations, including hyperglycemia, hypertension, osteoporosis, infection risk, adrenal suppression, ocular complications, and skin atrophy, making dose optimization, duration control, patient monitoring, and steroid-sparing strategies central to clinical decision-making. The corticosteroids therapy landscape is therefore defined by a dual priority: maintaining fast, reliable anti-inflammatory and immunosuppressive efficacy while reducing cumulative adverse effects through improved delivery systems, localized administration, rational prescribing, and integrated care protocols.

Transformative Shifts in the Corticosteroids Therapy Landscape

The corticosteroids therapy landscape is shifting from broad, prolonged systemic exposure toward more precise, indication-specific, and safety-conscious use. In respiratory care, inhaled and intranasal corticosteroids continue to support guideline-based management of asthma, allergic rhinitis, and selected chronic obstructive pulmonary disease phenotypes, with growing emphasis on adherence, inhaler technique, and combination regimens. In dermatology and ophthalmology, topical and localized corticosteroids are being used with stronger attention to potency selection, treatment cycling, and adverse-effect prevention. In rheumatology, gastroenterology, nephrology, and immunology, clinicians increasingly balance corticosteroid induction benefits with early transition to maintenance therapies that reduce long-term steroid burden. Hospital protocols are also becoming more standardized after extensive clinical experience with corticosteroids in severe inflammatory and respiratory complications, reinforcing the importance of appropriate patient selection and timing. Regulatory and clinical practice trends are strengthening pharmacovigilance, labeling clarity, pediatric caution, pregnancy-related risk assessment, and antimicrobial stewardship, since corticosteroids can modify immune responses. These shifts are encouraging manufacturers, healthcare systems, and prescribers to focus on differentiated formulations, patient education, digital adherence support, and real-world evidence generation rather than relying only on legacy prescribing patterns.

Cumulative Impact of Artificial Intelligence on Corticosteroids Therapy

Artificial intelligence is creating cumulative value across corticosteroids therapy by improving discovery, clinical decision support, pharmacovigilance, and patient management. In drug development, AI-enabled molecular modeling and computational biology can help evaluate receptor binding, tissue selectivity, formulation behavior, and potential off-target effects for next-generation corticosteroid candidates or delivery technologies. In clinical practice, AI-supported decision tools can analyze patient history, comorbidities, laboratory trends, medication profiles, exacerbation patterns, and imaging or spirometry data to support safer corticosteroid initiation, tapering, and monitoring, especially in complex inflammatory diseases. Natural language processing can identify corticosteroid-related adverse events in electronic health records, while predictive analytics can flag patients at higher risk of steroid-induced hyperglycemia, osteoporosis, infection, adrenal suppression, or poor adherence. AI also strengthens real-world evidence by integrating claims, registries, prescription data, and patient-reported outcomes to evaluate how corticosteroid regimens perform outside controlled trials. However, adoption must be governed by clinical validation, transparency, bias management, cybersecurity, and alignment with medical guidelines. The greatest impact is expected where AI augments clinician judgment, supports personalized dosing and safety surveillance, and helps reduce unnecessary corticosteroid exposure without compromising disease control.

Key Regional Insights Across Corticosteroids Therapy

Asia-Pacific is characterized by broad corticosteroids therapy utilization across respiratory disease, dermatology, ophthalmology, allergy care, and autoimmune indications, supported by large patient populations, expanding healthcare access, and strong reliance on affordable generic formulations. Countries with high air pollution exposure, smoking-related respiratory disease burden, and rising allergy prevalence are reinforcing the clinical role of inhaled, intranasal, and topical corticosteroids, while specialist care expansion is supporting more structured use in rheumatology, gastroenterology, and nephrology. Europe reflects highly regulated corticosteroid prescribing, robust safety labeling, strong primary care and specialist coordination, and continued movement toward localized delivery, pharmacovigilance monitoring, and reduced long-term systemic exposure. North America demonstrates mature adoption of guideline-driven corticosteroid protocols, strong adverse-event reporting systems, advanced specialty care access, and increasing emphasis on steroid-sparing approaches, chronic disease monitoring, and digital adherence tools. Latin America shows steady reliance on corticosteroids for acute and chronic inflammatory conditions, with access shaped by public reimbursement, private care availability, local formularies, and the need for stronger patient education around self-medication and appropriate treatment duration. Africa presents a heterogeneous environment in which corticosteroids are essential in primary, emergency, respiratory, dermatologic, and obstetric care, but availability, diagnostic capacity, affordability, and monitoring infrastructure vary widely, making rational prescribing, supply continuity, and adverse-event awareness critical priorities. In the Middle East, corticosteroids therapy is influenced by rising respiratory disease burden, allergy prevalence, diabetes-related monitoring needs, and expanding tertiary care infrastructure, particularly in health systems investing in specialty clinics, electronic medical records, and advanced diagnostics.

Key Group Insights Across Corticosteroids Therapy

NATO member countries, many of which overlap with high-income health systems, show significant emphasis on medicine security, emergency preparedness, hospital formularies, and standardized care pathways, supporting reliable access to corticosteroids for routine care, trauma settings, and acute inflammatory or respiratory emergencies. G7 countries generally demonstrate advanced evidence-based prescribing, high availability of multiple dosage forms, strong adverse-event reporting, and a growing preference for steroid-sparing treatment strategies where clinically appropriate, particularly in asthma, rheumatology, dermatology, inflammatory bowel disease, and transplant care. BRICS economies combine large patient bases, strong generic medicine use, expanding domestic pharmaceutical capabilities, and rising specialist care needs, making affordability, quality assurance, antimicrobial stewardship, and supply resilience central themes in corticosteroids therapy. The European Union benefits from harmonized regulatory oversight, pharmacovigilance infrastructure, and clinical guideline adoption, which encourages consistent safety monitoring, substitution standards, and rational corticosteroid use across member states, while variations in reimbursement and local prescribing culture still influence access. Within ASEAN, corticosteroids therapy is shaped by large populations, high respiratory and allergic disease burden, tropical dermatologic conditions, and expanding public health coverage, with continued need for clinician education on safe dosing, infection-related risk assessment, and patient adherence. The GCC has a strong focus on specialty care, hospital modernization, diabetes-aware prescribing, and chronic respiratory and autoimmune disease management, supporting uptake of advanced formulations and structured monitoring, particularly where digital health programs are being implemented.

Key Country Insights Across Corticosteroids Therapy

China has large-scale corticosteroid therapy use driven by respiratory disease, allergy, dermatology, ophthalmology, and autoimmune conditions, alongside continued investment in healthcare access, domestic manufacturing, and clinical standardization. The United States has extensive corticosteroids therapy use across primary care, emergency medicine, pulmonology, dermatology, rheumatology, gastroenterology, transplantation, and ophthalmology, with clinical attention centered on guideline adherence, steroid-sparing pathways, electronic prescribing controls, and monitoring for steroid-induced metabolic and bone complications. Japan is characterized by advanced specialty care, aging-related inflammatory and autoimmune disease management, and careful safety monitoring, while India has extensive use across asthma, dermatology, emergency care, autoimmune disease, and infectious-inflammatory differentials, making rational prescribing, affordability, diagnostic confidence, and patient education especially important. Germany demonstrates high clinical standardization, advanced specialty care, and careful pharmacovigilance, particularly in chronic inflammatory disease management, while the United Kingdom reflects structured prescribing through primary care and specialist guidelines, with strong attention to asthma control, oral corticosteroid stewardship, and adverse-effect monitoring. Australia demonstrates guideline-led corticosteroid use in asthma, allergy, dermatology, rheumatology, and ophthalmology, with strong primary care coordination. France maintains strong reimbursement systems and clinical oversight for corticosteroids, with emphasis on benefit-risk assessment and patient counseling, while South Korea combines sophisticated healthcare infrastructure, high digital health adoption, and broad access to corticosteroid dosage forms, supporting structured monitoring and adherence management. Italy and Spain show broad use in respiratory, rheumatologic, dermatologic, gastroenterologic, and ophthalmic indications, with increasing attention to aging populations, multimorbidity, and minimizing chronic systemic exposure. Canada emphasizes evidence-based prescribing, public and private reimbursement coordination, and chronic disease management, with inhaled, intranasal, topical, and systemic corticosteroids integrated into respiratory and dermatologic care. Russia relies on corticosteroids across hospital and outpatient settings, where availability of essential formulations and specialty access influences therapy patterns. Brazil combines a large public health system with significant respiratory, dermatologic, allergic, and autoimmune care needs, making access to cost-effective corticosteroid formulations and specialist referral pathways important, while Mexico shows strong use of corticosteroids in acute inflammation, allergy, respiratory disease, and dermatology, with opportunities to improve supervised use and reduce inappropriate self-medication.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize differentiated corticosteroid therapies that improve local delivery, reduce systemic exposure, and support safer long-term management in chronic inflammatory diseases. Product development should focus on optimized inhaled, intranasal, topical, ophthalmic, injectable, intra-articular, and modified-release formulations that address adherence, dosing convenience, onset of action, and tolerability. Evidence strategies should include real-world studies that evaluate adverse events, adherence, tapering outcomes, comorbidity risks, cumulative exposure, and patient-reported outcomes across diverse populations. Medical education should reinforce appropriate indication selection, shortest effective duration, tapering protocols, inhaler technique, topical potency guidance, and monitoring for metabolic, bone, ocular, dermatologic, endocrine, psychiatric, and infection-related risks. Digital tools can add value by supporting adherence reminders, symptom tracking, exacerbation alerts, electronic medication histories, and clinician dashboards for cumulative steroid exposure. Access teams should emphasize affordability, essential medicine availability, quality assurance, and reimbursement alignment, particularly in health systems with high generic reliance. Supply chain leaders should strengthen resilience for essential corticosteroid formulations used in emergency, primary care, maternal-fetal, respiratory, dermatologic, ophthalmic, and hospital settings. Finally, organizations should align innovation with steroid-sparing care models by positioning corticosteroids as part of integrated treatment pathways rather than isolated interventions.

Research Methodology

This executive summary is developed using a structured secondary research approach focused on verified clinical, regulatory, epidemiological, and healthcare delivery sources. The methodology includes review of peer-reviewed medical literature, clinical practice guidelines, pharmacovigilance frameworks, public health publications, medicine safety communications, essential medicines references, disease burden studies, and regulatory documentation relevant to corticosteroids therapy. Analysis considers therapeutic route, clinical indication, safety profile, prescribing behavior, healthcare infrastructure, access conditions, reimbursement context, and regional policy environments. Regional, group, and country insights are synthesized qualitatively to identify evidence-backed patterns in corticosteroid utilization, safety management, formulation preference, care pathway integration, and healthcare system readiness. The research deliberately excludes market estimation, market sizing, market share assessment, and forecasting to maintain focus on clinical and strategic intelligence. All insights are interpreted through the lens of practical decision-making for stakeholders involved in corticosteroid development, distribution, prescribing support, pharmacovigilance, and patient care optimization.

Conclusion

Corticosteroids therapy continues to be indispensable across acute and chronic inflammatory diseases, but its future depends on safer, more personalized, and more evidence-driven use. The field is moving toward localized delivery, reduced systemic burden, tighter monitoring, steroid-sparing care pathways, and better patient education. Artificial intelligence, real-world evidence, and digital health tools are strengthening the ability to identify risk, improve adherence, and guide individualized therapy decisions. Regional differences in healthcare access, regulation, specialist capacity, affordability, and pharmacovigilance will continue to shape corticosteroid use, particularly across emerging economies and resource-constrained settings. For industry leaders, the strongest opportunities lie in improving formulation performance, supporting rational prescribing, enhancing safety surveillance, strengthening supply continuity, and integrating corticosteroids into modern chronic disease management models. By balancing proven therapeutic value with disciplined risk reduction, corticosteroids therapy can remain a critical and trusted component of global healthcare.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Corticosteroids Therapy Market, by Drug Type

  • 7.1. Introduction
  • 7.2. Budesonide
  • 7.3. Dexamethasone
  • 7.4. Hydrocortisone
  • 7.5. Methylprednisolone
  • 7.6. Prednisone

8. Corticosteroids Therapy Market, by Route Of Administration

  • 8.1. Introduction
  • 8.2. Inhalation
    • 8.2.1. Dry Powder Inhaler
    • 8.2.2. Metered Dose Inhaler
    • 8.2.3. Nebulizer
  • 8.3. Injectable
    • 8.3.1. Intramuscular
    • 8.3.2. Intravenous
    • 8.3.3. Subcutaneous
  • 8.4. Oral
    • 8.4.1. Suspension
    • 8.4.2. Tablet
  • 8.5. Topical
    • 8.5.1. Cream
    • 8.5.2. Lotion
    • 8.5.3. Ointment

9. Corticosteroids Therapy Market, by Dosage Form

  • 9.1. Introduction
  • 9.2. Cream
  • 9.3. Injection
  • 9.4. Suspension
  • 9.5. Tablet

10. Corticosteroids Therapy Market, by Indication

  • 10.1. Introduction
  • 10.2. Allergic Rhinitis
  • 10.3. Asthma
  • 10.4. Dermatological Disorders
  • 10.5. Inflammatory Bowel Disease
  • 10.6. Rheumatoid Arthritis

11. Corticosteroids Therapy Market, by Patient Age Group

  • 11.1. Introduction
  • 11.2. Adult
  • 11.3. Geriatric
  • 11.4. Pediatric

12. Corticosteroids Therapy Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. Europe
  • 12.3. North America
  • 12.4. Latin America
  • 12.5. Africa
  • 12.6. Middle East

13. Corticosteroids Therapy Market, by Group

  • 13.1. NATO
  • 13.2. G7
  • 13.3. BRICS
  • 13.4. European Union
  • 13.5. ASEAN
  • 13.6. GCC

14. Corticosteroids Therapy Market, by Country

  • 14.1. China
  • 14.2. United States
  • 14.3. Japan
  • 14.4. India
  • 14.5. Germany
  • 14.6. United Kingdom
  • 14.7. Australia
  • 14.8. France
  • 14.9. South Korea
  • 14.10. Italy
  • 14.11. Canada
  • 14.12. Russia
  • 14.13. Brazil
  • 14.14. Mexico
  • 14.15. Spain

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2025
  • 15.2. FPNV Positioning Matrix, 2025
  • 15.3. Market Concentration Analysis, 2025
    • 15.3.1. Concentration Ratio (CR)
    • 15.3.2. Herfindahl Hirschman Index (HHI)
  • 15.4. Recent Developments & Impact Analysis, 2025
  • 15.5. Product Portfolio Analysis, 2025
  • 15.6. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Abbott Laboratories
  • 16.2. Allergan PLC
  • 16.3. Amgen Inc.
  • 16.4. AstraZeneca PLC
  • 16.5. Biogen Inc.
  • 16.6. Boehringer Ingelheim GmbH
  • 16.7. Bristol-Myers Squibb Company
  • 16.8. Cipla Inc.
  • 16.9. Dr. Reddy's Laboratories Ltd.
  • 16.10. Eli Lilly and Company
  • 16.11. Galderma Group
  • 16.12. Gilead Sciences, Inc.
  • 16.13. GlaxoSmithKline PLC
  • 16.14. Lupin Pharmaceuticals, Inc.
  • 16.15. Merck & Co., Inc.
  • 16.16. Mylan N.V.
  • 16.17. Novartis AG
  • 16.18. Pfizer Inc.
  • 16.19. Sanofi S.A.
  • 16.20. SANTHERA PHARMACEUTICALS
  • 16.21. Sun Pharmaceutical Industries Ltd.
  • 16.22. Takeda Pharmaceutical Company Limited
  • 16.23. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CORTICOSTEROIDS THERAPY MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL CORTICOSTEROIDS THERAPY MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL CORTICOSTEROIDS THERAPY MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL CORTICOSTEROIDS THERAPY MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY DRUG TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY DOSAGE FORM, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL CORTICOSTEROIDS THERAPY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 23. GLOBAL CORTICOSTEROIDS THERAPY MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL CORTICOSTEROIDS THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BUDESONIDE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BUDESONIDE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BUDESONIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DEXAMETHASONE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DEXAMETHASONE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DEXAMETHASONE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL HYDROCORTISONE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL HYDROCORTISONE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL HYDROCORTISONE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL METHYLPREDNISOLONE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL METHYLPREDNISOLONE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL METHYLPREDNISOLONE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PREDNISONE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PREDNISONE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PREDNISONE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL INHALATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL INHALATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL INHALATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DRY POWDER INHALER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DRY POWDER INHALER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DRY POWDER INHALER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL METERED DOSE INHALER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL METERED DOSE INHALER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL METERED DOSE INHALER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NEBULIZER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NEBULIZER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEBULIZER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL SUSPENSION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL SUSPENSION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL SUSPENSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL TABLET MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL TABLET MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL TABLET MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL TOPICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL TOPICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL TOPICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CREAM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CREAM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CREAM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL LOTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL LOTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL LOTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL OINTMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL OINTMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL OINTMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CREAM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CREAM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CREAM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL INJECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL INJECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL SUSPENSION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL SUSPENSION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL SUSPENSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL TABLET MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL TABLET MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL TABLET MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ALLERGIC RHINITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ALLERGIC RHINITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ALLERGIC RHINITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ASTHMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ASTHMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ASTHMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL DERMATOLOGICAL DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL DERMATOLOGICAL DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL DERMATOLOGICAL DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL INFLAMMATORY BOWEL DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL INFLAMMATORY BOWEL DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL INFLAMMATORY BOWEL DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ADULT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ADULT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC CORTICOSTEROIDS THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC CORTICOSTEROIDS THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC CORTICOSTEROIDS THERAPY MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC CORTICOSTEROIDS THERAPY MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC CORTICOSTEROIDS THERAPY MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC CORTICOSTEROIDS THERAPY MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC CORTICOSTEROIDS THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC CORTICOSTEROIDS THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC CORTICOSTEROIDS THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE CORTICOSTEROIDS THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE CORTICOSTEROIDS THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE CORTICOSTEROIDS THERAPY MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE CORTICOSTEROIDS THERAPY MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE CORTICOSTEROIDS THERAPY MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE CORTICOSTEROIDS THERAPY MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE CORTICOSTEROIDS THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE CORTICOSTEROIDS THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE CORTICOSTEROIDS THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST CORTICOSTEROIDS THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST CORTICOSTEROIDS THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST CORTICOSTEROIDS THERAPY MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST CORTICOSTEROIDS THERAPY MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST CORTICOSTEROIDS THERAPY MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST CORTICOSTEROIDS THERAPY MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST CORTICOSTEROIDS THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST CORTICOSTEROIDS THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST CORTICOSTEROIDS THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 166. NATO CORTICOSTEROIDS THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 167. NATO CORTICOSTEROIDS THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. NATO CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 169. NATO CORTICOSTEROIDS THERAPY MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 170. NATO CORTICOSTEROIDS THERAPY MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 171. NATO CORTICOSTEROIDS THERAPY MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 172. NATO CORTICOSTEROIDS THERAPY MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 173. NATO CORTICOSTEROIDS THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 174. NATO CORTICOSTEROIDS THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 175. NATO CORTICOSTEROIDS THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 176. G7 CORTICOSTEROIDS THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 177. G7 CORTICOSTEROIDS THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. G7 CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 179. G7 CORTICOSTEROIDS THERAPY MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 180. G7 CORTICOSTEROIDS THERAPY MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 181. G7 CORTICOSTEROIDS THERAPY MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 182. G7 CORTICOSTEROIDS THERAPY MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 183. G7 CORTICOSTEROIDS THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 184. G7 CORTICOSTEROIDS THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 185. G7 CORTICOSTEROIDS THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 186. BRICS CORTICOSTEROIDS THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 187. BRICS CORTICOSTEROIDS THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. BRICS CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS CORTICOSTEROIDS THERAPY MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS CORTICOSTEROIDS THERAPY MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS CORTICOSTEROIDS THERAPY MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS CORTICOSTEROIDS THERAPY MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS CORTICOSTEROIDS THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS CORTICOSTEROIDS THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS CORTICOSTEROIDS THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION CORTICOSTEROIDS THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION CORTICOSTEROIDS THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION CORTICOSTEROIDS THERAPY MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION CORTICOSTEROIDS THERAPY MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION CORTICOSTEROIDS THERAPY MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION CORTICOSTEROIDS THERAPY MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION CORTICOSTEROIDS THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPEAN UNION CORTICOSTEROIDS THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION CORTICOSTEROIDS THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN CORTICOSTEROIDS THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN CORTICOSTEROIDS THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN CORTICOSTEROIDS THERAPY MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN CORTICOSTEROIDS THERAPY MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN CORTICOSTEROIDS THERAPY MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN CORTICOSTEROIDS THERAPY MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN CORTICOSTEROIDS THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN CORTICOSTEROIDS THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 215. ASEAN CORTICOSTEROIDS THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 216. GCC CORTICOSTEROIDS THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 217. GCC CORTICOSTEROIDS THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. GCC CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 219. GCC CORTICOSTEROIDS THERAPY MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 220. GCC CORTICOSTEROIDS THERAPY MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 221. GCC CORTICOSTEROIDS THERAPY MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 222. GCC CORTICOSTEROIDS THERAPY MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 223. GCC CORTICOSTEROIDS THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 224. GCC CORTICOSTEROIDS THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 225. GCC CORTICOSTEROIDS THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 226. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 227. CHINA CORTICOSTEROIDS THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 228. CHINA CORTICOSTEROIDS THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. CHINA CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 230. CHINA CORTICOSTEROIDS THERAPY MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 231. CHINA CORTICOSTEROIDS THERAPY MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 232. CHINA CORTICOSTEROIDS THERAPY MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 233. CHINA CORTICOSTEROIDS THERAPY MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 234. CHINA CORTICOSTEROIDS THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 235. CHINA CORTICOSTEROIDS THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 236. CHINA CORTICOSTEROIDS THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES CORTICOSTEROIDS THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES CORTICOSTEROIDS THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED STATES CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED STATES CORTICOSTEROIDS THERAPY MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES CORTICOSTEROIDS THERAPY MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED STATES CORTICOSTEROIDS THERAPY MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED STATES CORTICOSTEROIDS THERAPY MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES CORTICOSTEROIDS THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED STATES CORTICOSTEROIDS THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED STATES CORTICOSTEROIDS THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 247. JAPAN CORTICOSTEROIDS THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 248. JAPAN CORTICOSTEROIDS THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. JAPAN CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 250. JAPAN CORTICOSTEROIDS THERAPY MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 251. JAPAN CORTICOSTEROIDS THERAPY MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 252. JAPAN CORTICOSTEROIDS THERAPY MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 253. JAPAN CORTICOSTEROIDS THERAPY MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 254. JAPAN CORTICOSTEROIDS THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 255. JAPAN CORTICOSTEROIDS THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 256. JAPAN CORTICOSTEROIDS THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 257. INDIA CORTICOSTEROIDS THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 258. INDIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. INDIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 260. INDIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 261. INDIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 262. INDIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 263. INDIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 264. INDIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 265. INDIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 266. INDIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 267. GERMANY CORTICOSTEROIDS THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 268. GERMANY CORTICOSTEROIDS THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 269. GERMANY CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 270. GERMANY CORTICOSTEROIDS THERAPY MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 271. GERMANY CORTICOSTEROIDS THERAPY MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 272. GERMANY CORTICOSTEROIDS THERAPY MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 273. GERMANY CORTICOSTEROIDS THERAPY MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 274. GERMANY CORTICOSTEROIDS THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 275. GERMANY CORTICOSTEROIDS THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 276. GERMANY CORTICOSTEROIDS THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED KINGDOM CORTICOSTEROIDS THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED KINGDOM CORTICOSTEROIDS THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 279. UNITED KINGDOM CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 280. UNITED KINGDOM CORTICOSTEROIDS THERAPY MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 281. UNITED KINGDOM CORTICOSTEROIDS THERAPY MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 282. UNITED KINGDOM CORTICOSTEROIDS THERAPY MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 283. UNITED KINGDOM CORTICOSTEROIDS THERAPY MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 284. UNITED KINGDOM CORTICOSTEROIDS THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 285. UNITED KINGDOM CORTICOSTEROIDS THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 286. UNITED KINGDOM CORTICOSTEROIDS THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 287. AUSTRALIA CORTICOSTEROIDS THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 288. AUSTRALIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 289. AUSTRALIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 290. AUSTRALIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 291. AUSTRALIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 292. AUSTRALIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 293. AUSTRALIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 294. AUSTRALIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 295. AUSTRALIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 296. AUSTRALIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 297. FRANCE CORTICOSTEROIDS THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 298. FRANCE CORTICOSTEROIDS THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 299. FRANCE CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 300. FRANCE CORTICOSTEROIDS THERAPY MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 301. FRANCE CORTICOSTEROIDS THERAPY MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 302. FRANCE CORTICOSTEROIDS THERAPY MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 303. FRANCE CORTICOSTEROIDS THERAPY MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 304. FRANCE CORTICOSTEROIDS THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 305. FRANCE CORTICOSTEROIDS THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 306. FRANCE CORTICOSTEROIDS THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 307. SOUTH KOREA CORTICOSTEROIDS THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 308. SOUTH KOREA CORTICOSTEROIDS THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 309. SOUTH KOREA CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 310. SOUTH KOREA CORTICOSTEROIDS THERAPY MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 311. SOUTH KOREA CORTICOSTEROIDS THERAPY MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 312. SOUTH KOREA CORTICOSTEROIDS THERAPY MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 313. SOUTH KOREA CORTICOSTEROIDS THERAPY MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 314. SOUTH KOREA CORTICOSTEROIDS THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 315. SOUTH KOREA CORTICOSTEROIDS THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 316. SOUTH KOREA CORTICOSTEROIDS THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 317. ITALY CORTICOSTEROIDS THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 318. ITALY CORTICOSTEROIDS THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 319. ITALY CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 320. ITALY CORTICOSTEROIDS THERAPY MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 321. ITALY CORTICOSTEROIDS THERAPY MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 322. ITALY CORTICOSTEROIDS THERAPY MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 323. ITALY CORTICOSTEROIDS THERAPY MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 324. ITALY CORTICOSTEROIDS THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 325. ITALY CORTICOSTEROIDS THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 326. ITALY CORTICOSTEROIDS THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 327. CANADA CORTICOSTEROIDS THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 328. CANADA CORTICOSTEROIDS THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 329. CANADA CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 330. CANADA CORTICOSTEROIDS THERAPY MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 331. CANADA CORTICOSTEROIDS THERAPY MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 332. CANADA CORTICOSTEROIDS THERAPY MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 333. CANADA CORTICOSTEROIDS THERAPY MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 334. CANADA CORTICOSTEROIDS THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 335. CANADA CORTICOSTEROIDS THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 336. CANADA CORTICOSTEROIDS THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 337. RUSSIA CORTICOSTEROIDS THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 338. RUSSIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 339. RUSSIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 340. RUSSIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 341. RUSSIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 342. RUSSIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 343. RUSSIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 344. RUSSIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 345. RUSSIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 346. RUSSIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 347. BRAZIL CORTICOSTEROIDS THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 348. BRAZIL CORTICOSTEROIDS THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 349. BRAZIL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 350. BRAZIL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 351. BRAZIL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 352. BRAZIL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 353. BRAZIL CORTICOSTEROIDS THERAPY MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 354. BRAZIL CORTICOSTEROIDS THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 355. BRAZIL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 356. BRAZIL CORTICOSTEROIDS THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 357. MEXICO CORTICOSTEROIDS THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 358. MEXICO CORTICOSTEROIDS THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 359. MEXICO CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 360. MEXICO CORTICOSTEROIDS THERAPY MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 361. MEXICO CORTICOSTEROIDS THERAPY MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 362. MEXICO CORTICOSTEROIDS TH